These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Ipser JC; Sander C; Stein DJ Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD005332. PubMed ID: 19160252 [TBL] [Abstract][Full Text] [Related]
27. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder. Uzun O; Ozdemir B Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402 [TBL] [Abstract][Full Text] [Related]
28. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Seedat S; Stein DJ Int Clin Psychopharmacol; 1999 Nov; 14(6):353-6. PubMed ID: 10565802 [TBL] [Abstract][Full Text] [Related]
29. Premenstrual syndrome: a single-blind study of treatment with buspirone versus fluoxetine. Nazari H; Yari F; Jariani M; Marzban A; Birgandy M Arch Gynecol Obstet; 2013 Mar; 287(3):469-72. PubMed ID: 23073723 [TBL] [Abstract][Full Text] [Related]
30. The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases. Thomsen PH; Mikkelsen HU Eur Child Adolesc Psychiatry; 1999 Jun; 8(2):143-8. PubMed ID: 10435463 [No Abstract] [Full Text] [Related]
31. Update on pharmacologic management of OCD: agents and augmentation. McDougle CJ J Clin Psychiatry; 1997; 58 Suppl 12():11-7. PubMed ID: 9393391 [TBL] [Abstract][Full Text] [Related]
32. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Carpenter LL; McDougle CJ; Epperson CN; Price LH Drug Saf; 1996 Aug; 15(2):116-34. PubMed ID: 8884163 [TBL] [Abstract][Full Text] [Related]
33. [Neurobiology and pharmacotherapy of social phobia]. Aouizerate B; Martin-Guehl C; Tignol J Encephale; 2004; 30(4):301-13. PubMed ID: 15538306 [TBL] [Abstract][Full Text] [Related]
34. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ BMC Psychiatry; 2005 Jan; 5():5. PubMed ID: 15667657 [TBL] [Abstract][Full Text] [Related]
35. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567 [TBL] [Abstract][Full Text] [Related]
36. Possible serotonin syndrome associated with buspirone added to fluoxetine. Manos GH Ann Pharmacother; 2000; 34(7-8):871-4. PubMed ID: 10928399 [TBL] [Abstract][Full Text] [Related]